I like the following reply to the standard model of a successful pharm startup
[COLOR=rgba(0, 0, 0, 0.75)]I suppose one of the questions that you and the board will face is at what point do you sell a business to big pharma or perhaps one of your competitors. You've got to pick the moment I suppose because it's at what point are you going to maximise the return?
Yeah, Alan, that's not the focus of what we're doing. We're looking at how do we develop and commercialise and make profits out of our own product which was developed by the CSIRO. Cochlear and CSL are very successful Australian multi-nationals as is Ansell. There's no particular reason why PolyNovo couldn't follow a similar path and be another successful Australian multi-national. The best way to run your company and the best way to get value in your company is to run it as your own commercial entity as effectively and aggressively as you can.
good and aggressive answer the management has a dream and vision that ticks the boxes[/COLOR]
- Forums
- ASX - By Stock
- PNV
- Kohler interview
Kohler interview, page-6
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.04 |
Change
-0.030(1.45%) |
Mkt cap ! $1.699B |
Open | High | Low | Value | Volume |
$2.09 | $2.11 | $2.03 | $1.727M | 838.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 307227 | $2.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.04 | 5605 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 70013 | 2.420 |
1 | 7548 | 2.410 |
6 | 29644 | 2.400 |
2 | 9566 | 2.390 |
2 | 6018 | 2.380 |
Price($) | Vol. | No. |
---|---|---|
2.430 | 2062 | 1 |
2.440 | 12548 | 2 |
2.450 | 16199 | 3 |
2.460 | 10569 | 3 |
2.470 | 2021 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
PNV (ASX) Chart |